ERBB2 and breast carcinoma: This includes the identification and regulation of novel therapeutic targets and breast cancer-associated markers, such as estrogen [71], progesterone [72], HER2 [73,74], CCL18 [75], miR-31 [76], melatonin [77], or WNT5A [78] and others.